The Central Role of Inflammation Associated with Checkpoint Inhibitor Treatments

Table 1

Indications for administration of nivolumab 480 mg every 4 weeks [51].

---

Indications—nivolumab 480 mg every 4 weeks

 (i) Metastatic melanoma
 (ii) Previously treated NSCLC
 (iii) Advanced renal cell carcinoma treated with prior antiangiogenic therapy
 (iv) Locally advanced or metastatic urothelial carcinoma which was previously treated, with progression during or after platinum-based chemotherapy
 (v) Classical Hodgkin lymphoma following relapse/progression after autologous hematopoietic stem cell transplantation (HSCT) and brentuximab vedotin or three or more lines of systemic therapy that includes autologous HSCT
 (vi) Recurrent/metastatic squamous cell carcinoma of the head and neck following platinum-based therapy
 (vii) Hepatocellular carcinoma after prior sorafenib therapy
 (viii) Adjuvant therapy for patients with completely resected melanoma with lymph node involvement or metastatic disease

---